Search Results 571-580 of 18423 for Prostate cancer
The purpose of this study is to compare the effects (good and bad) on patients with prostate cancer by comparing the standard dose of radiation therapy (44 ...
The purpose of this study is to determine the safety of the NanoKnife treatment in prostate cancer tissue when used in a low and intermediate risk patient ...
This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC).
PSA levels go up when the prostate becomes enlarged. But higher PSA levels also can be due to recent procedures, illnesses, surgery or prostate cancer. Urinary ...
to strain more to urinate. Dr. Cheney says prostate enlargement, or BPH, does not mean cancer. "It is truly just enlargement, and the cells in the prostate are ...
"The reality is that prostate cancer is the most commonly diagnosed solid malignancy in men," says Dr. Eugene Kwon, a Mayo Clinic urologist. Dr. Kwon says, ...
Prostate cancer is treatable and potentially curable when detected early. National Prostate Cancer Awareness Month encourages men to discuss screening with ...
... tumor cell. Giving 177Lu-PSMA-617 for 5 cycles versus 6 cycles may better treat patients with metastatic castrate resistant prostate cancer. Participation ...
By looking at the genetic makeup of individual men with prostate cancer, Mayo Clinic is helping doctors know which drugs may help. ... If you're about to undergo ...
About this study. This is an open label, phase I/II, multi-center study in adult participants with metastatic hormone sensitive prostate cancer (mHSPC) and ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.